Diclofenac epolamine - IBSA
Alternative Names: DHEP - IBSA; Diclofenac epolamine topical system 1.3% - Institut Biochemique SA; Diclofenac epolamine transdermal patch - Institut Biochemique SA; Diclofenac-N-(2-hydroxyethyl)-pyrrolidine - IBSA; Effigel; Flector EP Tissugel; Flector Patch; Flector Tissugel; LicartLatest Information Update: 28 Sep 2022
At a glance
- Originator IBSA
- Class Analgesics; Aniline compounds; Antirheumatics; Benzene derivatives; Chlorinated hydrocarbons; Nonsteroidal anti-inflammatories; Phenylacetates; Pyrrolidines; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute pain; Pain
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Pain(In volunteers) in Switzerland (PO, Tablet)
- 06 Jun 2022 Phase-III clinical trials in Pain (In adults, In the elderly) in Poland (Topical) (EudraCT2021-006465-38)
- 31 Oct 2021 Phase-III clinical trials in Pain (In adolescents, In adults, In children) in USA (Topical) (NCT05171673)